Abbott Laboratories A/S

2 similar searches for Abbott Laboratories A/S

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

8.679 documents for Abbott Laboratories A/S

- Fitch Places Abbott Laboratories' L-T Ratings on Negative Watch; Affirms S-T Ratings.
CHICAGO -- Fitch Ratings has placed Abbott Laboratories' (ABT's) Long-term ratings on Negative Watch. In addition, Fitch has affirmed ABT's Short-term...
- Business Wire
- May 07, 2012
- the Regents of the University of California, Abbott Molecular Inc., and Abbott Laboratories Inc., Plaintiffs-Petitioners, v. Dako North America, Inc. and Dako A/S, Defendants-Respondents., 477 F.3d 1335 (Fed. Cir. 2007)
Lynn H. Pasahow, Fenwick & West LLP, of Mountain View, CA, for plaintiffs-petitioners. Of counsel were Carolyn Chang, C.J. Alice Chuang, Virginia K. D...
- Federal Circuits
- Fitch Places Abbott Laboratories' L-T Ratings On Negative Watch; Affirms S-T Ratings
Fitch Ratings Primary Analyst
- Business Wire
- May 07, 2012

- Similac Maker May Be Liable for Infant's Brain Damage, Rules U.S. District Court in Iowa
The maker of a powder infant formula may be liable for brain damage suffered by a newborn who contracted a form of meningitis after being fed the company's product, a U.S. District Court in Iowa has ruled in denying a motion to dismiss. The plaintiff is the conservator for a child who suffered severe brain damage due to E. sakazakii meningitis that she contracted ten days after being born. The onset of the illness coincided with her ingesting infant formula made with Similac powder, an Abbott Laboratories product. The Similac formula was sent home with the child's mother in a hospital gift bag.
- Lawyers USA
- February 16, 2012
- Research and Markets: Abbott Laboratories Medical Equipment Company Share Analysis Report Provides an Analysis of Abbott's Key Revenue Lines.
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/af22b9/abbott_laboratorie) has announced the addition of the "Abbo...
- Business Wire
- October 03, 2008
- New York Ag Announces $54m Settlement Against Illinois-Based Pharmaceutical Giant
Two separate settlements with Illinois-based pharmaceutical giant Abbott Laboratories were announced Monday by Attorney General Eric T. Schneiderman. The cases involve the marketing and sale of the anti-seizure drug Depakote for unapproved uses. The first is a $1.5 billion global settlement with other states and the federal government to settle civil and criminal allegations that Abbott Laboratories illegally marketed Depakote. New York's share is $50 million. The second is a $100 million settlement reached by Schneiderman with 44 other state attorneys general and the District of Columbia from alleged improper marketing and promotion of Depakote.
- Daily Record (Rochester, NY)
- May 15, 2012
- Drink Manufacturer to Bring 240 Jobs ; $12.9 Million Payroll Expected for Jobs at New Ensure, Glucerna Plant.
TIPP CITY -- Abbott Laboratories' journey to last week's announcement of plans to build a $270 million nutritional drinks manufacturing plant off County Road 25A started with information the city provided on a state Internet listing of industrial sites. Details of the effort to attract the plant and 240 jobs along with local incentives for the Chicago-area based company were outlined March 2 for Tipp City Council at the beginning of a daylong planning retreat.
- Dayton Daily News
- March 08, 2012
- Zacks Releases Four Powerful 'Buy' Stocks: St. Jude Medical, Abbott Laboratories, The Children's Place and Posco.
CHICAGO -- Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1...
- Business Wire
- July 24, 2008
- A Decade of Change
If you look at where big drugs are going to be 10 years from now, virtually all of them are coming out of the biotech world," says G. Steven Burrill, CEO of Burnii & Company, a life sciences venture capital and financial services firm. Abbott Laboratories, ranked #14 in this year's survey, for example, will lose its patent for the cholesterol- and triglyceride-reducing drug TriCor in July 2012, while the patent for #17 Novartis's high blood pressure medicine Diovan will expire in September 2012, costing the companies some $68 million and $1.5 billion a year, respectively.
- Scientist, The
- July 06, 2012
- Schaeffer's Midday Options Update Features Schering-Plough, Goody's Family Clothing, Albertson's, Abbott Laboratories, and PepsiCo.
CINCINNATI -- Today's Schaeffer's Midday Options Update features Schering-Plough (NYSE:SGP), Goody's Family Clothing (NASDAQ:GDYS), Albertson's (NYSE:...
- Business Wire
- November 22, 2005